How many clinical trials are studying SHR-A2102?

6 recruiting trials in our tracked data involve SHR-A2102.

What conditions is SHR-A2102 being studied for?

In our tracked recruiting trials, SHR-A2102 is being studied in trials for Breast Cancer, Advanced Breast Cancer, HER2-negative Breast Cancer.

Recruiting trials

Conditions studied

US states with sites

Countries

Phase 1 1 Phase 2 6

Condition	Trials
Breast Cancer · SHR-A2102 for Breast Cancer	4
Advanced Breast Cancer · SHR-A2102 for Advanced Breast Cancer	3
HER2-negative Breast Cancer	2
Lung cancer	2
Non-Small Cell Lung Cancer	2
Breast Neoplasm	1
Hormone Receptor Positive Tumor	1
Metastatic Breast Cancer	1
Triple Negative Breast Cancer (TNBC)	1
Triple-negative Breast Cancer	1

A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06589778 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
NCT07229729 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT06649331 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Reverse Triple Negative Immune Resistant Breast Cancer
NCT05076682 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
NCT05594095 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
NCT06433609 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location